Insider Selling: CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells $214,899.72 in Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Andrew Schwab sold 45,147 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $4.76, for a total value of $214,899.72. Following the transaction, the director directly owned 2,579,998 shares in the company, valued at approximately $12,280,790.48. The trade was a 1.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

CAMP4 Therapeutics Stock Performance

CAMP4 Therapeutics stock opened at $4.48 on Monday. The company has a market capitalization of $281.12 million, a P/E ratio of -1.93 and a beta of 0.22. CAMP4 Therapeutics Corporation has a fifty-two week low of $1.41 and a fifty-two week high of $7.75. The stock has a 50-day simple moving average of $4.12 and a 200-day simple moving average of $4.34.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. As a group, analysts forecast that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

CAMP has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. JPMorgan Chase & Co. raised shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Finally, Chardan Capital set a $6.50 target price on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, CAMP4 Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $9.56.

Institutional Investors Weigh In On CAMP4 Therapeutics

Several hedge funds have recently modified their holdings of CAMP. China Universal Asset Management Co. Ltd. purchased a new position in CAMP4 Therapeutics in the 4th quarter valued at $61,000. Jefferies Financial Group Inc. acquired a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth $70,000. Bank of America Corp DE purchased a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at about $86,000. OMERS ADMINISTRATION Corp acquired a new position in shares of CAMP4 Therapeutics during the fourth quarter worth about $115,000. Finally, Goldman Sachs Group Inc. purchased a new position in CAMP4 Therapeutics during the fourth quarter worth about $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.